BioPharma Dive
Backed by OrbiMed, Novartis venture arm and many other investors, the biotech is among those working on newer technology that could broaden the reach of antibody-drug conjugates.
BioPharma Dive
Backed by OrbiMed, Novartis venture arm and many other investors, the biotech is among those working on newer technology that could broaden the reach of antibody-drug conjugates.
BioPharma Dive
Backed by OrbiMed, Novartis venture arm and many other investors, the biotech is among those working on newer technology that could broaden the reach of antibody-drug conjugates.